Cardlytics, Inc.
DE ˙ DB ˙ US14161W1053
0,45 € ↓ -0,04 (-8,23%)
2026-06-05
DEL PRIS
SecurityDE:CYX / Cardlytics, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership61,720 shares
Latest Disclosed Value $ 64,806
Goldman Sachs Group Inc reports 43.38% decrease in ownership of CYX / Cardlytics, Inc.

On May 15, 2026 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 61,720 shares of Cardlytics, Inc. (DE:CYX) valued at $45,710 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 109,001 shares of Cardlytics, Inc.. This represents a change in shares of -43.38% during the quarter. The current value of the position is $27,527 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CARDLYTICS CMN 14161W105 61,720 -47,281 -43.38 65 -48.80 0.0000
2026-02-10 2025-12-31 13F CARDLYTICS CMN 14161W105 109,001 14,273 15.07 125 -45.65 0.0000
2025-11-14 2025-09-30 13F CARDLYTICS CMN 14161W105 94,728 -92,607 -49.43 230 -25.32 0.0000
2025-08-14 2025-06-30 13F CARDLYTICS CMN 14161W105 187,335 63,632 51.44 308 36.89 0.0000
2025-06-27 2025-03-31 13F/A-2 CARDLYTICS CMN 14161W105 123,703 -58,370 -32.06 225 -66.67 0.0000
2025-05-16 2025-03-31 13F/A-1 CARDLYTICS CMN 14161W105 123,703 -58,370 225 0.0000
2025-05-09 2025-03-31 13F CARDLYTICS CMN 14161W105 123,703 -58,370 225 0.0000
2025-02-11 2024-12-31 13F CARDLYTICS CMN 14161W105 182,073 -45,302 -19.92 675 -7.15 0.0001
2024-11-14 2024-09-30 13F CARDLYTICS CMN 14161W105 227,375 -102,359 -31.04 728 -73.14 0.0001
2024-08-13 2024-06-30 13F CARDLYTICS CMN 14161W105 329,734 184,497 127.03 2,707 28.66 0.0005
2024-05-15 2024-03-31 13F CARDLYTICS CMN 14161W105 145,237 -151,440 -51.05 2,104 -22.99 0.0004
2024-05-14 2023-12-31 13F/A-2 CARDLYTICS CMN 14161W105 296,677 40,911 16.00 2,732 -35.26 0.0005
2024-03-01 2023-12-31 13F/A-1 CARDLYTICS CMN 14161W105 296,677 40,911 2,732 0.0005
2024-02-13 2023-12-31 13F CARDLYTICS CMN 14161W105 296,677 40,911 2,732 0.0005
2024-05-15 2023-09-30 13F/A-1 CARDLYTICS CMN 14161W105 255,766 112,545 78.58 4,220 366.30 0.0009
2023-11-14 2023-09-30 13F CARDLYTICS CMN 14161W105 255,766 112,545 4,220 0.0008
2024-05-14 2023-06-30 13F/A-1 CARDLYTICS CMN 14161W105 143,221 23,365 19.49 905 122.91 0.0002
2023-08-15 2023-06-30 13F CARDLYTICS CMN 14161W105 143,221 23,365 905 0.0002
2024-05-14 2023-03-31 13F/A-1 CARDLYTICS CMN 14161W105 119,856 -6,623 -5.24 407 -44.46 0.0001
2023-05-11 2023-03-31 13F CARDLYTICS CMN 14161W105 119,856 -6,623 407 0.0001
2024-05-14 2022-12-31 13F/A-1 CARDLYTICS CMN 14161W105 126,479 -189,381 -59.96 731 36,450.00 0.0002
2023-02-13 2022-12-31 13F CARDLYTICS CMN 14161W105 126,479 -189,381 731 0.0002
2024-05-14 2022-09-30 13F/A-1 CARDLYTICS CMN 14161W105 315,860 41,919 15.30 3 -66.67 0.0008
2022-11-14 2022-09-30 13F CARDLYTICS CMN 14161W105 315,860 41,919 2,969 0.0007
2024-05-14 2022-06-30 13F/A-2 CARDLYTICS CMN 14161W105 273,941 67,734 32.85 6 -99.95 0.0015
2022-08-18 2022-06-30 13F/A-1 CARDLYTICS CMN 14161W105 273,941 67,734 6,111 0.0014
2022-08-15 2022-06-30 13F CARDLYTICS CMN 14161W105 273,941 67,734 6,111 0.0014
2022-05-16 2022-03-31 13F CARDLYTICS CMN 14161W105 206,207 133,670 184.28 11,337 136.48 0.0024
2022-02-17 2021-12-31 13F/A-1 CARDLYTICS CMN 14161W105 72,537 -69,859 -49.06 4,794 -59.89 0.0010
2022-02-14 2021-12-31 13F CARDLYTICS CMN 14161W105 72,537 -69,859 4,794 0.0003
2022-01-20 2021-09-30 13F/A-1 CARDLYTICS CMN 14161W105 142,396 -684 -0.48 11,953 -34.18 0.0025
2021-11-10 2021-09-30 13F CARDLYTICS CMN 14161W105 142,396 -684 11,953 0.0007
2021-08-13 2021-06-30 13F CARDLYTICS CMN 14161W105 143,080 34,344 31.58 18,161 52.26 0.0041
2021-05-17 2021-03-31 13F CARDLYTICS CMN 14161W105 108,736 -14,958 -12.09 11,928 -32.46 0.0030
2021-02-12 2020-12-31 13F CARDLYTICS CMN 14161W105 123,694 -22,853 -15.59 17,660 70.76 0.0045
2020-11-13 2020-09-30 13F CARDLYTICS CMN 14161W105 146,547 -49,028 -25.07 10,342 -24.44 0.0029
2020-08-12 2020-06-30 13F CARDLYTICS CMN 14161W105 195,575 19,491 11.07 13,687 122.37 0.0042
2020-05-15 2020-03-31 13F CARDLYTICS CMN 14161W105 176,084 132,582 304.77 6,155 125.13 0.0022
2020-02-14 2019-12-31 13F CARDLYTICS CMN 14161W105 43,502 -62,259 -58.87 2,734 -22.88 0.0007
2019-11-14 2019-09-30 13F CARDLYTICS CMN 14161W105 105,761 97,493 1,179.16 3,545 1,548.84 0.0010
2019-08-14 2019-06-30 13F CARDLYTICS CMN 14161W105 8,268 8,268 215 0.0001
2018-08-14 2018-06-30 13F CARDLYTICS CMN 14161W105 0 -21,561 -100.00 0 -100.00
2018-05-15 2018-03-31 13F CARDLYTICS CMN 14161W105 21,561 21,561 315 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.